SHORT REPORT

DOI: 10.4244/EIJ-D-18-00036

Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre

Gretchen Stern1, PharmD, BCPS; Jessica Rimsans1, PharmD, BCPS; Arman Qamar2, MD; Muthiah Vaduganathan2, MD, MPH; Deepak L. Bhatt2*, MD, MPH

Introduction

Oral antiplatelet therapy may require temporary disruption soon after percutaneous coronary intervention (PCI) or acute coronary syndrome, incurring potential thrombotic risks. Glycoprotein IIb/IIIa inhibitors have been used for “bridging”, but limited safety data are available1. The BRIDGE (Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery) trial demonstrated that cangrelor, a fast-acting intravenous P2Y12 inhibitor, could be safely used to maintain platelet inhibition prior to cardiac surgery2. Although parenteral antiplatelet bridging was highlighted in recent expert consensus documents3,4, guidelines do not provide clear recommendations, and limited comparative data are available between agents5.

Methods

We identified patients receiving antiplatelet bridging from October 2015 to June 2017 in a large, tertiary care centre. Parenteral agents used specifically for bridging or when extended beyond the duration indicated for PCI (4 hours for cangrelor and 24 hours for eptifibatide) were included. Primary bridge indications were identified via review of clinical records. On-therapy stent thrombosis, coronary reocclusion, Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-defined or Bleeding Academic Research Consortium (BARC)-defined bleeding6, and deaths were collected and adjudicated by two investigators. Appropriate bridge dosing for cangrelor was based on the BRIDGE trial’s dosing (0.75 μg/kg/min), and appropriate eptifibatide was determined by the package insert (2 μg/kg/min, dose reduced to 1 μg/kg/min for creatinine clearance ≤50 mL/min).

Results

Thirty-one patients (9 eptifibatide, 20 cangrelor, and 2 both) were included. Two patients received eptifibatide and then were transitioned to cangrelor due to its lower perceived bleeding risk. All but one patient remained on maintenance aspirin therapy during the bridge period. Median age was 63 years and 73% were men (Supplementary Table 1). On admission, 54% presented in cardiogenic shock and 26% with cardiac arrest. During hospitalisation, 71% required mechanical ventilation and 49% required mechanical circulatory support. Eighty-seven percent had a prior coronary stent; median time from last stent was 17 (2-64) days. All unstented patients (13%) were being evaluated for unplanned coronary artery bypass grafting (CABG). Primary bridge therapy indications included surgery (68%), limited enteral absorption/access (16%), and high perceived bleed risk (16%) (Figure 1). Median duration of bridge therapy was 61 (25th-75th percentile 20-100) hours in the cangrelor group and 83 (25th-75th percentile 19-98) hours in the eptifibatide group.

Figure 1. Primary indications for antiplatelet bridging. GI: gastrointestinal

GUSTO severe/life-threatening bleeding and thrombotic events were not observed. GUSTO mild/moderate bleeding occurred in 30% of cangrelor-treated patients and 27% of eptifibatide-treated patients. Of the nine patients who underwent CABG, none experienced BARC type 4 bleeding. No patients required an invasive procedure for bleeding events. Death during index hospitalisation occurred in five (16%) patients. Initial supratherapeutic dosing occurred in five cangrelor-treated patients related to use of doses indicated for PCI (4 μg/kg/min) and there was one case of contraindicated eptifibatide use in end-stage renal disease. Initial subtherapeutic dosing due to renal function occurred in one eptifibatide-treated patient (1 mcg/kg/min). Mild/moderate bleeding occurred in three of five patients with dosing errors during cangrelor treatment.

Discussion

Parenteral antiplatelet bridging with cangrelor or eptifibatide was being employed for ~3 days in this single-centre experience. The most frequent indication was unplanned surgery following PCI (typically within 30 days). Despite high-risk presentations with >15% in-hospital mortality, efficacy profiles were reassuring with no identified stent thrombosis. Differences between groups, including the numerically higher risk of moderate bleeding observed with cangrelor use (compared with eptifibatide), should be cautiously interpreted, given variation in indications for use, concurrent antithrombotic therapies, small sample sizes, and dosing errors.

Antiplatelet bridging is associated with excess bleeding and cost, regardless of strategy, and should be reserved only for select, high-risk cases. When required, therapeutic practices need to be standardised and clinicians should become familiar with indications, bridging doses, and necessary renal adjustments. To mitigate dosing errors, we recommend that all bridge dosing regimens be determined collaboratively by a cardiologist and a pharmacist; this may be crucial when drugs are used “off label” at a dose that differs from standard doses. Patients with renal impairment or unclear timing of surgery may benefit from cangrelor’s rapid, non-renal clearance.

Limitations

This was a small, single-centre, retrospective study intended to inform initial patterns of use of parenteral antiplatelet therapies. Larger, prospective, multicentre studies are required regarding risks of stent thrombosis with oral antiplatelet disruption, approaches to attenuate on-therapy bleeding, and the optimal strategy during this high-risk window.

Conclusion

At this juncture, antiplatelet bridging should only be used in well-selected patients at the appropriate dose for the minimal necessary treatment duration.

Impact on daily practice

We present the first real-world experience of cangrelor use for antiplatelet bridging at a tertiary care centre. Although stent thrombosis was not observed during bridging, bleeding and dosing errors were commonly encountered.

Conflict of interest statement

A. Qamar and M. Vaduganathan are supported by the NHLBI T32 postdoctoral training grant (T32HL007604). D.L. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: AHA Quality Oversight Committee; Data Monitoring Committees: Cleveland Clinic, DCRI, HCRI, Mayo Clinic, Mount Sinai School of Medicine, PHRI; Honoraria: ACC (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), DCRI (clinical trial steering committees), HCRI (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), JACC (Guest Editor; Associate Editor), PHRI (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, Abbott; Trustee: ACC; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda. The other authors have no conflicts of interest to declare.

Supplementary data

Supplementary Table 1. Patient profiles, bridging indications, and on-treatment clinical events in antiplatelet bridging recipients.

To read the full content of this article, please download the PDF.


References

Volume 14 Number 3
Jun 14, 2018
Volume 14 Number 3
View full issue


Key metrics

Suggested by Cory

Debate

10.4244/EIJ-E-23-00070 Apr 1, 2024
Guideline recommendations for cangrelor should be upgraded: pros and cons
Dangas G et al
free

Research correspondence

10.4244/EIJ-D-22-00594 Mar 20, 2023
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry
Gargiulo G et al
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved